Latest news

RCD advises AlbaJuna Therapeutics, an IrsiCaixa spin-off, on the inflow of capital that will fund the development of antibodies against HIV
DWF-RCD news

RCD – Rousaud Costas Duran has advised AlbaJuna Therapeutics, a spin-off from the IrsiCaixa AIDS Research Institute, on the investment of €3.75M by the pharmaceutical company Grifols, which will support the development of therapeutic antibodies to fight HIV. The amount invested is expected to increase as each molecule development stage is completed.